Suppr超能文献

初次左心室辅助装置植入后器械更换:适应证和结果。

Device exchange after primary left ventricular assist device implantation: indications and outcomes.

机构信息

Division of Cardiovascular Surgery, Mayo Clinic College of Medicine, Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA.

出版信息

Ann Thorac Surg. 2013 Apr;95(4):1262-7; discussion 1267-8. doi: 10.1016/j.athoracsur.2012.08.031. Epub 2012 Oct 11.

Abstract

BACKGROUND

Patients are being supported for longer periods with implantable left ventricular assist devices (LVADs) owing to longer transplantation wait times and approval of LVADs for destination therapy. This comes with an increased potential need for device exchange when complications arise. There are few data examining this patient population.

METHODS

Between August 1998 and January 2012, 45 patients (34 men) underwent 57 device exchanges after primary pulsatile or continuous-flow LVAD implantation. The median age at the initial LVAD implantation was 58 years (range, 28-78 years) and the median time to first device exchange was 15 months (range, immediate-56 months). Indications for primary LVAD included bridge to transplantation in all but 10 patients, and devices included the HeartMate I (Thoratec, Pleasanton, CA) in 16 patients, the HeartMate II (Thoratec) in 21 patients, the HeartWare HVAD (HeartWare, Framingham, MA) in 2 patients, the DuraHeart I (Terumo Heart, Ann Arbor, MI) in 1 patient, and other devices in 5 patients. Indications for reoperation included device/component failure (n=24), major driveline infection (n=15), pump thrombus (n=15), and other indications (n=2).

RESULTS

Pumps implanted in 57 reoperations included the HeartMate I in 15 patients, the HeartMate II in 35 patients, the HeartWare HVAD in 2 patients, the DuraHeart I in 2 patients, and other devices in 3 patients. Early mortality occurred in 2/57 (3.5%) patients. Median follow-up was 18 months (range, 1-113 months); median length of LVAD therapy after the first device exchange was 13 months (range, 1-59 months). Actuarial 1-year survival and freedom from repeated device exchange after the first exchange was 89% and 79%, respectively.

CONCLUSIONS

Device exchange may be required after LVAD implantation. This can be performed with low early mortality and no adverse effect on late survival. Multiple reoperations may be required in some patients.

摘要

背景

由于移植等待时间延长和批准将 LVAD 用于终末期治疗,越来越多的患者需要使用植入式左心室辅助装置(LVAD)进行更长时间的支持。这就增加了出现并发症时需要更换设备的潜在需求。目前很少有数据检查这一患者群体。

方法

1998 年 8 月至 2012 年 1 月期间,45 名患者(34 名男性)在首次植入搏动性或连续性 LVAD 后进行了 57 次设备更换。初次 LVAD 植入时的中位年龄为 58 岁(范围为 28-78 岁),首次设备更换的中位时间为 15 个月(范围为即刻至 56 个月)。初次 LVAD 的适应证均为桥接移植,除 10 例患者外,还包括 HeartMate I(Thoratec,Pleasanton,CA)16 例,HeartMate II(Thoratec)21 例,HeartWare HVAD(HeartWare,Framingham,MA)2 例,DuraHeart I(Terumo Heart,Ann Arbor,MI)1 例,以及其他设备 5 例。再手术的适应证包括设备/组件故障(n=24)、严重的动力线感染(n=15)、泵血栓形成(n=15)和其他适应证(n=2)。

结果

57 例再手术中植入的泵包括 HeartMate I 15 例、HeartMate II 35 例、HeartWare HVAD 2 例、DuraHeart I 2 例、其他设备 3 例。57 例患者中,2 例(3.5%)早期死亡。中位随访时间为 18 个月(范围为 1-113 个月);首次设备更换后 LVAD 治疗的中位时间为 13 个月(范围为 1-59 个月)。1 年生存率和首次更换后无重复设备更换的生存率分别为 89%和 79%。

结论

LVAD 植入后可能需要进行设备更换。这种方法具有较低的早期死亡率,且对晚期生存率没有不良影响。一些患者可能需要多次再手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验